Stallergenes Greer able to resume manufacturing at Antony plant

2 February 2016

Biopharma company Stallergenes Greer (Euronext Paris: STAGR), which specializes in treatments for respiratory allergies, yesterday announced that the manufacturing and distribution of immunotherapies Oralair, Actair and Alyostal venom is starting after a temporary suspension at its Stallergenes SAS plant in Antony, France.

The company was forced to shut down its site and recall every product released since August 13 (The Pharma Letter December 15, 2015). The situation was caused by technical problems which have plagued the firm since it set up a new IT system at its allergy immunotherapy manufacturing plant in Antony. These operational disruptions have now been satisfactorily addressed, the company noted.

The suspension resulted in a shortage of supply for many doctors and allergy immunotherapy patients in France, and is likely to have benefitted rivals such as Denmark’s ALK-Abello. Just last week, a Stallergenes spokesperson told The Pharma Letter that it was progressing in talks with the French health authority with a view to resuming operations as soon as possible (TPL January 27).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK